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ABSTRACT			 In	previous	experiments,	the	steroidal	saponin,	dioscin,	which	was	extracted	from	the	roots	of	the	wild	yam	(Dioscorea	villosa),	was	observed	to	have	potent	anti-proliferative	effects	on	the	human	breast	cancer	cell	lines	MCF-7	and	MDA-MB-231.	Dioscin	was	also	able	to	activate	the	transcription	of	tumor	suppressor	genes	GATA3	and	CDH1	in	these	cell	lines.	We	hypothesize	that	the	anti-proliferative	effect	of	dioscin	on	human	breast	cancer	cells	could	be	mediated	through	the	epigenome.		Consequently,	in	order	to	explore	this	hypothesis,	we	have	analyzed	the	expression	of	DNA	methyltransferase	1	(DNMT1)	protein	in	these	cells.	MCF-7	and	MDA-MB-231	cells	were	treated	with	differing	concentrations	of	dioscin,	as	well	as	a	1μM	concentration	of	the	known	DNMT1	inhibitor,	5-azacytidine.	Protein	lysate	was	collected	from	these	cells	and	was	then	subjected	to	Western	blot	analysis.	Both	dioscin	and	5-azacytidine	decreased	protein	expression	of	the	DNMT	isoform	with	a	molecular	weight	of	145	kDa.	It	may	be	concluded	that	dioscin	has	potential	DNMT1	inhibiting	ability,	but	whether	or	not	this	ability	directly	contributes	to	dioscin’s	anti-proliferative	effects	and	the	activation	of	the	tumor	suppressor	genes	GATA3	and	CDH1	remains	to	be	seen.		 		
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Introduction	
	 Breast	cancer	has	become	one	of	the	most	frequently	diagnosed	cancers	in	the	United	States	today.	The	American	Cancer	Society	estimates	that	1	in	8	women	will	acquire	invasive	breast	cancer	in	their	lifetime,	making	it	the	second	most	prevalent	cancer	in	women	behind	skin	cancer.	Although	the	mortality	rate	has	dropped	over	the	years,	breast	cancer	is	responsible	for	40,000	deaths	per	year	in	the	United	States	alone	(Lu	et	al.	2009).	These	deaths	are	mostly	attributed	to	the	reoccurrence	of	the	cancer,	which	frequently	present	with	metastases	(Lu	et	al.	2009).	Metastatic	breast	cancer	today	is	generally	treated	with	a	cocktail	of	cytotoxic	drugs	that	can	immensely	reduce	the	patient’s	quality	of	life	and	allow	the	cancer	to	develop	a	drug	resistance	quite	quickly.		The	search	for	a	viable	anti-cancer/anti-metastatic	agent	is	still	very	much	alive	due	to	the	devastating	side	effects	of	most	known	drugs.	For	many	years,	it	was	thought	that	the	mechanisms	behind	breast	cancer	were	genetic	alterations.	In	other	words,	breast	cancer	resulted	from	direct	changes	in	the	DNA	code,	such	as	deletions,	point	mutations,	and	chromosome	rearrangements	(Aumsuwan	et	al.	2016).	However,	it	is	now	known	that	breast	cancer	not	only	arises	from	genetic	alterations,	but	also	from	epigenetic	modifications	(Aumsuwan	et	al.	2016).	Epigenetics	is	a	rapidly	growing	field	in	
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cancer	research,	mainly	because	epigenetic	modifications	are	enzyme-regulated	processes;	they	do	not	affect	the	primary	DNA	sequence	and	are	able	to	be	reversed,	making	epigenetic	drugs	an	exciting	prospect	for	cancer	therapies.	The	most	common	types	of	epigenetic	alterations	are	histone	modifications,	DNA	methylation,	and	noncoding	RNA	interface	(Aumsuwan	et	al.	2016).	While	all	of	these	epigenetic	mechanisms	have	been	found	to	be	altered	in	cancer	cells,	we	know	the	most	about	DNA	methylation	and	will	focus	mainly	on	this	process.		DNA	methylation	is	an	epigenetic	mechanism	where	a	methyl	group	(CH3)	is	added	to	the	DNA,	thereby	altering	the	function	of	a	gene.	In	mammals,	DNA	methylation	occurs	mostly	on	C-5	of	cytosine	at	CpG	sites,	which	are	cytosine-guanine	(CG)	dinucleotide	sequences	associated	with	gene	promoters	(Carey,	2013).	When	these	CpG	sites	are	not	extensively	methylated,	the	chromatin	structure	is	loosely	packed,	the	gene	promoter	region	is	unhindered,	and	transcription	of	the	gene	proceeds	(Neidhart,	2016).	In	contrast,	when	CpG	sites	are	highly	methylated,	chromatin	structure	becomes	compacted,	transcription	activators	are	unable	to	bind	to	the	promoter	region,	and	gene	transcription	is	shut	off	(Neidhart,	2016).	DNA	methylation	therefore	provides	an	efficient	way	to	regulate	gene	expression,	because	the	effects	are	reversible.	Cancers	are	able	to	abuse	this	regulation	pathway,	however,	by	altering	the	promoter	regions	of	tumor	suppressor	genes,	proto-oncogenes,	and	other	genes	associated	with	DNA	repair	pathways	(Carey,	2013).	When	the	promoter	regions	on	tumor	suppressor	genes	and	DNA	repair	genes	are	highly	methylated,	the	genes	are	inactivated	and	tumor	growth	is	unable	to	be	held	in	check.	In	breast	cancer	alone,	over	100	different	tumor	suppressor	
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genes	have	been	shown	to	be	hypermethylated	(Hinshelwood	et	al.	2008).	Cancers	are	able	to	accomplish	this	uncontrolled	tumorigenesis	by	hijacking	the	enzymes	responsible	for	DNA	methylation.		It	is	now	documented	that	breast	cancer,	along	with	various	other	cancers,	is	able	to	silence	tumor	suppressor	genes	through	the	abnormal	functioning	and	expression	of	DNA	methyltransferases	(DNMTs)(Aumsuwan	et	al.	2015).	These	enzymes	catalyze	the	addition	of	methyl	groups	to	the	CpG	sites,	and	function	in	the	maintenance	of	genomic	stability.	There	are	three	different	DNMTs	that	possess	this	enzymatic	activity:	DNMT1,	DNMT3A,	and	DNMT3B.	DNMT1	is	described	as	the	“maintenance”	methyltransferase	and	is	the	most	prevalent	DNMT	in	somatic	cells	(Robertson	et	al.	2001).	The	“maintenance”	activity	refers	to	the	ability	of	the	methyltransferase	to	recognize	hemimethylated	DNA	and	add	the	corresponding	methyl	group	to	the	complementary	strand	(Chen	et	al.	2011).	For	this	reason,	DNMT1	is	generally	responsible	for	maintaining	DNA	methylation	patterns	after	DNA	replication	has	occurred.	DNMT3A	and	DNMT3B	comprise	the	family	of	what	is	known	as	the	de	novo	methyltransferases.	These	DNMTs	add	methyl	groups	to	completely	unmethylated	DNA,	and	are	in	charge	of	setting	the	patterns	of	methylation	early	on	in	development	and	in	cell	differentiation	(Chen	et	al.	2011).	The	roles	of	the	maintenance	and	de	novo	DNMTs	do	show	some	overlap,	however,	as	DNMT3A	and	DNMT3B	may	be	able	methylate	certain	CpG	sites	that	were	skipped	over	by	DNMT1	(Chen	et	al.	2011).	In	addition	to	these	three	catalytically	conserved	enzymes,	there	are	two	other	DNMTs	in	the	human	body	that	need	mentioning.	DNMT3L	does	not	possess	any	inherent	enzymatic	activity,	but	it	is	able	
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to	recruit	DNMT3A/3B	and	stimulate	their	activity	(Chen	et	al.	2011).		A	separate	methyltransferase,	DNMT2,	has	not	been	shown	to	be	very	active	in	DNA	methylation,	but	instead	has	been	shown	to	methylate	tRNAs	and	protect	them	from	cleavage	(Ghanbarian	et	al.	2016).	Although	these	two	methyltransferases	are	a	part	of	the	DNMT	family,	they	do	not	directly	catalyze	the	addition	of	a	methyl	group	to	CpG	sites	in	humans.															
Figure	1:	A:	The	addition	of	a	C-5	methyl	group	catalyzed	by	DNMT.	B:	The	mechanisms	of	maintenance	methylation	by	DNMT1	vs	de	novo	methylation	by	DNMT3A/3B.	(Chen	et	al.	2011)		
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Although	the	exact	mechanisms	are	still	unknown,	cancers	are	able	to	atypically	express	these	DNMTs	and	disturb	normal	DNA	methylation	patterns	(Jin	
et	al.	2013).	A	recent	study	was	able	to	demonstrate	that	DNMT1	is	overexpressed	in	mammary	tumors	and	is	essential	for	both	mammary	stem	cell	and	cancer	stem	cell	maintenance	(Pathania	et	al.	2015).	In	the	experiment,	they	introduced	a	mammary-gland	specific	DNMT1	gene	deletion	to	mice	predisposed	to	breast	cancer,	and	85%	of	the	mice	were	protected.	Although	the	breast	development	was	suppressed,	the	DNMT1	gene	deleted	mice	had	a	significantly	higher	survival	rate	than	those	who	retained	the	DNMT1	gene	in	their	mammary	gland	(Pathania	et	al.	2015).	These	results	indicate	that	DNMT1	expression	in	mammary	cells	could	prove	to	be	an	effective	target	in	limiting	tumorigenesis	in	the	breast.		Different	epigenetic	drugs	have	been	created	over	the	years	in	hopes	of	limiting	DNMT	activity,	but	no	exceptional	cancer	treatment	has	been	found.	The	epigenetic	drug	5-azacytidine	(AZA)	is	a	known	nucleoside	DNMT	inhibitor	that	was	approved	by	the	US	Food	and	Drug	Administration	to	treat	myelodysplastic	syndrome	(Amatori	et	al.	2010).	AZA	is	one	of	the	few	known	DNMT	inhibiting	drugs	and	is	currently	in	a	number	of	clinical	trials	to	test	its	efficacy	for	the	treatment	of	haematological	cancers.	Although	AZA	was	first	synthesized	over	4	decades	ago,	the	mechanisms	behind	this	epi-drug	were	not	fully	understood	until	quite	recently.	AZA’s	effectiveness	and	anti-cancer	ability	stems	from	its	core	structure,	which	is	notably	similar	to	the	structure	of	the	nucleoside	base,	cytosine.		
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Figure	2:	The	similar	structures	of	Cytosine	and	5-Azacytosine.	Note	the	substitution	of	a	Nitrogen	atom	at	C-5.		(Borin	et	al.	2017)			 Once	it	has	been	internalized	into	the	cell,	AZA	is	able	to	incorporate	itself	into	either	DNA	or	RNA	by	taking	the	place	of	a	cytosine	base	(Amatori	et	al.	2010).	Specifically	in	DNA	incorporation,	after	DNA	replication	takes	place,	DNMT1	enzymes	proceed	with	their	maintenance	methylation,	but	problems	arise	as	they	encounter	AZA	bases	in	the	DNA.		When	a	DNMT1	binds	to	an	AZA	base,	the	enzyme	is	unable	to	add	a	methyl	group	because	the	C-5	of	AZA	is	replaced	with	a	Nitrogen	atom	(Carey,	201).	The	DNMT1	becomes	covalently	stuck	to	the	AZA	base	and	is	later	degraded,	therefore	reducing	the	amount	of	DNMT1	available	(Carey,	201).	This	binding	and	degradation	of	DNMT1	leads	to	a	passive	decrease	in	methylation	and	the	re-expression	of	tumor	suppressor	genes	and	apoptotic	pathway	genes	that	had	been	previously	silenced	by	hypermethylation	(Amatori	et	al.	2010).		However,	AZA,	like	many	other	potential	anti-cancer	drugs,	has	a	dangerous	toxicity	profile	and	a	high	level	of	instability	under	physiological	conditions	(Amatori	et	al.	2010).	It	
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must	be	taken	in	very	low	doses	to	avoid	extreme	cytotoxicity.	If	another	DNMT	inhibiting	compound	was	found	to	be	similarly	effective	and	have	limited	adverse	effects,	it	could	prove	to	be	a	novel	cancer	therapeutic.		Natural	products	are	an	encouraging	area	of	research	because	many	natural	compounds	have	exhibited	chemopreventive	characteristics	while	maintaining	a	low	toxicity	profile.	There	are	numerous	herbal	remedies	that	have	shown	promise	in	the	treatment	of	cancer,	and	some	molecules	derived	from	natural	products	have	already	been	reported	as	having	DNMT	inhibiting	abilities.	The	marine	sponge	
Pseudoceratina	purpurea	contains	several	derivatives	that	exhibit	DNMT1	inhibitory	abilities,	as	does	a	type	of	red	alga	by	the	name	of	Peyssonnelia	caulifera	(Medina-Franco	et	al.	2010).	The	National	Center	for	Natural	Products	Research	here	at	the	University	of	Mississippi	has	taken	a	special	interest	in	the	roots	and	rhizomes	of	the	plant	Dioscorea	villosa,	also	known	as	the	wild	yam.	Found	throughout	the	Eastern	United	States,	Dioscorea	villosa	is	commonly	used	as	a	dietary	supplement	to	treat	menstrual	cramps	and	menopausal	symptoms,	but	has	recently	shown	promise	as	an	anti-cancer	agent	(Aumsuwan	et	al.	2015).	The	roots	and	rhizomes	of	Dioscorea	
villosa	are	rich	in	steroidal	saponins;	some	of	these	saponins	show	promise	as	anti-cancer	agents	(Aumsuwan	et	al.	2016).		Dioscorea	villosa	root	extract	was	recently	found	to	decrease	the	cell	viability	in	several	breast	cancer	cell	lines,	and	was	identified	as	a	possible	demethylating	agent	(Aumsuwan	et	al.	2015).	Further	examination	into	the	components	of	the	root	extract	revealed	that	the	bioactive	compound	dioscin	was	a	major	factor	responsible	for	this	epigenetic	activity.			
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Figure	3:	The	chemical	structure	of	Dioscin.	(Aumsuwan	et	al.	2016)		 Dioscin	(DS)	is	a	steroidal	saponin	that	has	been	reported	to	possess	anti-inflammatory,	hepatoprotective,	and	antiviral	effects	(Wu	et	al.	2015;	Zhang	et	al.	2015;	Liu	et	al.	2012).	DS	has	also	been	shown	to	possess	anti-proliferative	and	apoptotic	abilities	in	a	variety	of	cancer	cells	(Aumsuwan	et	al.	2016).	In	a	previous	study	(Aumsuwan	et	al.	2016),	DS	was	found	to	reduce	cell	proliferation	in	two	separate	breast	cancer	cell	lines:	MCF-7	(estrogen	receptor	positive;	noninvasive)	and	MDA-MB-231	(estrogen	receptor	negative;	invasive).	A	RT-qPCR	was	also	utilized	to	determine	the	effect	of	DS	and	AZA	(a	known	DNMT	inhibitor)	on	the	mRNA	content	of	two	commonly	hypermethylated	tumor	suppressor	genes	in	breast	cancer:	GATA3	and	CDH1.	DS	and	AZA	were	ineffective	in	altering	GATA3	and	CDH1	mRNA	expression	in	the	MCF-7	cell	line,	but	both	DS	and	AZA	were	able	to	significantly	increase	GATA3	and	CDH1	mRNA	content	in	the	MDA-MB-231	cells.	These	results	first	tell	us	that	the	cellular	effects	of	DS	and	AZA	treatments	are	cell	line	specific.	In	addition,	these	results	indicate	that	DS	may	be	able	to	alter	the	
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methylation	status	on	the	GATA3	and	CDH1	gene	promoters	in	invasive	breast	cancer	cells.	An	additional	RT-qPCR	was	run	to	examine	the	mRNA	content	of	DNMT1	in	MCF-7	and	MDA-MB-231	cells	treated	with	DS,	and	no	significant	change	was	found.	From	these	results,	it	was	hypothesized	that	DS	may	have	anti-cancer	potential	similar	to	AZA	because	it	is	able	to	affect	gene	methylation	and	re-express	tumor	suppressor	genes	that	were	previously	silenced.		The	research	I	conducted	is	essentially	an	extension	of	what	was	found	in	the	paragraph	above.	Because	DS	and	AZA	had	similar	effects	in	the	breast	cancer	cell	lines,	I	wanted	to	determine	if	DS	is	able	to	work	through	a	similar	mechanism	as	AZA,	and	if	so,	if	DS	could	be	a	novel	and	safe	breast	cancer	therapeutic.	DNMT1	was	the	apparent	starting	point	because	of	its	critical	role	in	cell	maintenance,	and	because	it	is	known	to	be	overexpressed	in	mammary	tumors.	Therefore,	the	goal	of	my	experiment	was	to	determine	if	DS	is	able	to	inhibit	DNMT1	protein	expression	in	breast	cancer	cells.			 					
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Materials	and	Methods	
	
Plant	Material	Dioscin	(3β,	25R)-spirost-5-en-3-yl	O-α-L-rhamnopyranosyl-(1	→	2)-O-[α-L-rhamnopyranosyl-(1	→	4)]-β-D-glucopyranoside)	was	isolated	at	the	National	Center	for	Natural	Products	Research	(NCNPR),	University	of	Mississippi,	Mississippi,	USA;	the	identity	and	purity	(91.2%)	were	confirmed	by	chromatographic	and	spectral	analysis.	
	
	
Cell	Culture	Human	breast	cancer	adenocarcinoma,	MCF-7	(ER+)	and	MDA-MB-231	(ER-)	cell	lines	were	purchased	from	American	Type	Culture	Collection	(ATCC).	Both	cell	lines	were	maintained	in	phenol	red	free	DMEM-F12	(1:1)	medium	supplemented	with	10%	dextran	charcoal	treated	fetal	bovine	serum	(Atlanta	Biologicals,	Atlanta,	GA),	50	U/mL	penicillin	and	50	μg/mL	streptomycin	as	Pen-Strep	(Life	Technology,	Grand	Island,	NY),	and	2	mM	of	L-glutamine	(Life	Technology)	at	37°C in	a	humidified	atmosphere	of	95%	air	and	5%	CO2.	To	maintain	both	cell	lines	in	identical	culture	conditions,	human	recombinant	insulin	(0.01	mg/mL)	was	omitted	for	MCF-7	cells.	The	cells	(~400	x	103	cells/mL)	were	allowed	to	attach	in	the	
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culture	flasks,	and	after	24	hours	were	treated	with	various	concentrations	of	DS	(3,	6	μM)	or	AZA	(1μM)(Sigma-Aldrich,	St.	Louis,	MO)	as	a	known	inhibitor	of	DNMT	enzyme	activities	for	three	days.	The	media	of	the	cells	treated	with	AZA	were	replaced	every	24	hours.	After	total	removal	of	the	media	at	72	hours	of	treatment,	the	cells	were	trypsinized,	resuspended	in	the	medium,	washed	twice	with	PBS,	and	were	used	for	biochemical	analysis.	(Aumsuwan	et	al.	2016)			
Cell	Lysis	Cells	were	put	on	ice	and	kept	at	a	temperature	of	4°C.	The	medium	was	removed	by	aspiration	and	cells	were	washed	twice	with	PBS.	Cells	were	treated	with	150	μL	lysis	buffer	(1	mL	10x	protease	inhibitor,	9	mL	lysis	buffer)	and	allowed	to	incubate	for	1	hour	at	4°C.	Cells	were	mechanically	removed	via	scraping	and	centrifuged	at	12,000	rpm	for	20	minutes.	Supernatant	was	gathered	and	protein	concentration	was	measured	via	Bradford	protocol.				
Western	Blot	Lysate	samples	were	boiled	in	sample	buffer	and	loaded	onto	SDS-PAGE	gel	(BioRad)	with	a	concentration	of	25	μg	of	protein	in	each	well.		The	gel	was	run	at	70	V,	400	mA	for	2	hours,	and	was	then	transferred	onto	a	blotting	membrane	and	placed	in	a	blocking	solution	(Invitrogen;	BSA	based)	overnight	at	4°C.	The	membrane	was	rinsed	and	allowed	to	incubate	with	the	polyclonal	rabbit	DNMT1	
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IgG	antibody	(1:100;	Santa	Cruz	Biotechnology;	sc-20701)	for	24	hours	at	4°C.	WesternDot™	625	Western	Blot	Kit	from	Invitrogen	was	then	utilized	for	immunodetection	of	proteins.		With	washing	in	between	each	step,	the	membrane	was	incubated	with	the	goat	anti-rabbit	IgG	secondary	antibody	(5:12000)	for	1	hour	at	4°C	and	the	Qdot®	625	streptavidin	conjugate	(5:12000)	for	1	hour	at	4°C.	Pictures	were	taken	of	the	membrane	and	analyzed.	Anti-beta	Actin	antibody	(Cell	Signaling)	was	utilized	as	a	loading	control. 				
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Results	and	Observations	
	Two	separate	Western	blots	were	run	to	give	an	accurate	representation	of	dioscin’s	effects	on	the	DNMT1	protein.	For	each	Western	blot,	both	cell	lines	received	the	following	treatments:	Dimethyl	sulfoxide	(DMSO)	only,	1μM	AZA,	3μM	DS,	and	6μM	DS.	Both	DS	and	AZA	had	been	resuspended	in	DMSO	in	their	stock	solutions,	so	the	DMSO	only	treatment	served	as	our	control.	This	made	sure	that	the	observed	results	were	due	to	DS	and	AZA,	and	not	due	to	the	DMSO.		The	image	of	Western	blot	1	(Figure	4)	was	taken	September	28,	2016.	The	MDA-MB-231	cells	proved	to	be	much	more	fragile	in	culture	than	the	MCF-7	cells.	The	treatment	of	6μM	DS	was	found	to	be	toxic	to	the	MDA-MB-231	cells,	and	we	were	not	able	to	collect	enough	lysate	for	western	blot	analysis.	Therefore,	the	treatment	of	6μM	DS	was	omitted	for	the	MDA-MB-231	cells	in	Western	blot	1	(Figure	4).	Two	separate	isoforms	of	DNMT1	protein	were	detected	on	the	membrane,	which	is	consistent	with	the	background	information	given	by	Santa	Cruz	Biotechnology	and	expected	because	of	the	polyclonal	nature	of	the	antibody.	The	first	isoform	(A)	was	detected	at	roughly	145	kDa,	while	the	second	isoform	(B)	was	detected	at	120	kDA.	The	loading	control	was	confirmed	to	be	accurate,	as	the	beta	Actin	bands	(C)	were	located	at	the	expected	weight	of	45	kDa.			
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Figure	4:		Western	blot	1	analysis	of	the	cell	lines	MCF-7	(lanes	2-6)	and	MDA-MB-231	(lanes	7-10)	with	selected	treatments.	Lane	1:	molecular	weight	markers;	Lane	2:	MCF-7,	DMSO;	Lane	3:	MCF-7,	1μM	AZA;	Lane	4:	MCF-7,	6μM	DS;	Lane	5:	MCF-7,	3μM	DS;	Lane	6:	MCF-7,	untreated;	Lane	7:	MDA-MB-231,	DMSO;	Lane	8:	MDA-MB-231,	1μM	AZA;	Lane	9:	MDA-MB-231,	3μM	DS;	Lane	10:	MDA-MB-231,	untreated.			 The	image	of	Western	blot	2	(Figure	5)	was	taken	November	11,	2016.	The	MDA-MB-231	cells	responded	more	favorably	to	the	6μM	DS	treatment,	and	we	were	able	to	collect	enough	lysate	for	western	blot	analysis.	The	6μM	DS	lane	was	therefore	added	for	the	MDA-MB-231	cell	line	in	Western	blot	2	(Figure	5,	lane	8).	The	two	DNMT1	isoforms	(A,B)	were	detected	at	145	kDa	and	120	kDa,	and	the	beta	Actin	bands	were	again	located	at	45	kDa.	While	there	is	a	significant	amount	of	non-specific	binding	and	background	noise	in	between	the	beta	Actin	bands	and	the	
													Lane:					1										2											3												4											5										6											7												8											9										10	
A	
B	
	
	
	
	
C	
						75	kDa													25	kDa		
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DNMT1	bands,	this	can	be	chiefly	attributed	to	the	polyclonal	nature	of	the	DNMT1	antibody.	If	a	monoclonal	antibody	were	used,	the	binding	would	be	much	more	specific.		
	
Figure	5:	Western	blot	2	analysis	of	cell	lines	MCF-7	(lanes	2-5)	and	MDA-MB-231	(Lanes	6-9)	with	selected	treatments.	Lane	1:	molecular	weight	markers;	Lane	2:	MCF-7,	DMSO;	Lane	3:	MCF-7,	1μM	AZA;	Lane	4:	MCF-7,	6μM	DS;	Lane	5:	MCF-7,	3μM	DS;	Lane	6:	MDA-MB-231,	DMSO;	Lane	7:	MDA-MB-231,	1μM	AZA;	Lane	8:	MDA-MB-231,	6μM	DS;	Lane	9:	MDA-MB-231	3μM	DS.				 The	intensities	of	the	DNMT1	protein	bands	were	quantified	using	the	Bio-Rad	ChemiDoc	MP	Imaging	System.	The	intensities	for	each	of	the	treatments	were	normalized	in	terms	of	the	control	(DMSO	only),	and	relative	intensity	ratios	were	developed	to	analyze	the	DNMT1	protein	concentrations.		
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Table	1:	Relative	intensity	ratios	of	DNMT1	protein	bands	for	Western	blot	1.	
Treatment	 Antibody	 Cell	line	 First	Isoform	 Second	Isoform	
DMSO	 DNMT1	 MCF7	 1.00	 1.00	
1uM	AZA	 DNMT1	 MCF7	 0.39	 0.64	
6uM	DS	 DNMT1	 MCF7	 0.78	 0.72	
3uM	DS	 DNMT1	 MCF7	 1.04	 1.00	
DMSO	 DNMT1	 MDAMB231	 1.00	 1.00	
1uM	AZA	 DNMT1	 MDAMB231	 0.68	 1.07	
3uM	DS	 DNMT1	 MDAMB231	 0.47	 1.41			
Table	2:	Relative	intensity	ratios	of	DNMT1	protein	bands	for	Western	blot	2.		
Treatment	 Antibody	 Cell	line	 First	Isoform	 Second	Isoform	
DMSO		 DNMT1	 MCF7	 1.00	 1.00	
1uM	AZA	 DNMT1	 MCF7	 0.21	 0.76	
6uM	DS	 DNMT1	 MCF7	 0.51	 0.90	
3uM	DS	 DNMT1	 MCF7	 0.54	 1.00	
DMSO	 DNMT1	 MDAMB231	 1.00	 1.00	
1uM	AZA	 DNMT1	 MDAMB231	 0.63	 1.13	
6uM	DS	 DNMT1	 MDAMB231	 0.70	 1.21	
3uM	DS	 DNMT1	 MDAMB231	 0.68	 1.11			The	results	in	Table	1	and	Table	2	indicate	that	DS	and	AZA	were	able	to	decrease	the	protein	concentration	of	the	first	isoform	of	DNMT1	in	both	the	MCF-7	cells	and	the	MDA-MB-231	cells.	However,	only	the	1μM	AZA	and	the	6μM	DS	treatments	were	able	to	inhibit	the	protein	expression	of	the	second	DNMT1	isoform.	These	relationships	are	more	clearly	depicted	by	Figure	6.	
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Figure	6:	Mean	expression	of	DNMT1	protein	(±	average	deviation)	for	Western	blots	1	and	2.	
 
Figure 6 demonstrates that DS and AZA were much more effective in decreasing 
the protein expression of the first DNMT1 isoform in both the MCF-7 and MDA-MB-
231 cell lines. Protein expression for both DNMT1 isoforms exhibited a dose dependent 
response to DS in the MCF-7 cells. AZA was also able to decrease the protein expression 
of the first isoform of DNMT1 by 70% and the second isoform of DNMT1 by 30%. 
Protein expression in the MDA-MB-231 cells did not exhibit a dose dependent response 
to DS. DS and AZA were able to decrease protein expression of the first isoform of 
DNMT1 in the MDA-MB-231 cells, but they actually increased protein expression of the 
second isoform of DNMT1.   
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Table	3:	The	percent	increase/decrease	of	DNMT1	protein	concentration	in	breast	cancer	cells.		
	
MCF7		 		 MDAMB231	 		
Treatment	
		
DNMT1	
isoform	1	
DNMT1	
isoform	2	
DNMT1	
isoform	1	
DNMT1	
isoform	2	
AZA	1uM	 70%	decrease	 30%	decrease	 34%	decrease	 10%	increase	
DS	3uM	 21%	decrease	 no	decrease	 30%	decrease	 26%	increase	
DS	6uM	 36%	decrease	 19%	decrease	 42%	decrease	 21%	increase																																		
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Discussion	
	
	
	 The	present	study	was	focused	on	the	steroidal	saponin,	dioscin,	and	its		efficacy	as	a	DNMT1	inhibitor.	The	results	obtained	from	the	two	Western	blot	experiments	are	not	perfect,	but	they	are	promising.	DS	was	able	to	inhibit	the	protein	expression	of	both	isoforms	of	DNMT1	in	MCF-7	cells	and	the	protein	expression	of	the	first	isoform	(145	kDa)	of	DNMT1	in	MDA-MB-231	cells.	DS	and	AZA	exhibited	similar	effects	on	the	DNMT1	protein	concentration,	as	we	hoped	they	would.	These	complementary	results	reinforce	our	hypothesis	that	DS	is	a	potential	DNMT1	inhibitor.	It	can	also	be	concluded	that	DS	is	acting	post-transcriptionally	to	inhibit	DNMT1	protein	expression.	We	know	this	because	the	mRNA	content	of	DNMT1	in	MCF-7	and	MDA-MB-231	cells	remained	unaltered	when	treated	with	DS	(Aumsuwan	et	al.	2016).	Therefore,	DS	may	be	acting	on	the	DNMT1	mRNA	and	inhibiting	some	step	of	translation,	or	DS	may	be	directly	degrading	the	DNMT1	protein	with	a	mechanism	similar	to	AZA’s.			 While	these	results	support	our	hypothesis	that	DS	is	a	DNMT1	inhibitor,	there	are	still	some	questions	that	remain.	DS	was	able	to	inhibit	DNMT1	protein	expression	in	the	MCF-7	cells;	this	was	not	expected	considering	that	in	a	previously	conducted	experiment,	DS	increased	GATA3	and	CDH1	mRNA	expression	in	the	MDA-MB-231	cells	but	not	in	the	MCF-7	cells	(Aumsuwan	et	al.	2016).	For	this	reason,	DS’s	inhibition	of	DNMT1	may	not	be	the	only	contributing	factor	in	the	re-
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expression	of	GATA3	and	CDH1.	Analysis	of	DS’s	effect	on	other	epigenetic	proteins	may	be	needed	in	order	to	explain	the	exact	mechanism	by	which	DS	is	able	to	re-express	these	tumor	suppressor	genes.			 DS	is	a	proven	anti-breast	cancer	agent	in	vitro.	It	is	able	to	reduce	cell	proliferation	and	increase	expression	of	crucial	tumor	suppressor	genes.	Whether	or	not	DS’s	anti-breast	cancer	potential	stems	solely	from	its	DNMT1	inhibiting	activity	remains	to	be	seen,	but	there	is	a	clear	path	to	follow	in	order	to	determine	this.	The	effect	of	DS	on	other	epigenetic	proteins	involved	in	methylation	and	demethylation	must	be	determined.	DS’s	impact	on	DNMT3A	and	DNMT3B	protein	expression	should	be	examined,	as	well	as	its	impact	on	other	DNMT	binding	proteins	and	the	recently	discovered	TET	enzymes.	As	our	knowledge	in	the	field	of	epigenetics	increases,	so	will	our	knowledge	on	epigenetic	mechanisms	and	drug	treatments.	DS	may	one	day	be	used	as	an	anti-invasive	therapeutic	in	the	treatment	of	breast	cancer,	but	we	have	yet	to	elucidate	the	exact	mechanism	of	action	or	how	it	will	perform	in	an	animal	model.	For	now,	DS	is	a	promising	and	natural	anti-cancer	agent	with	the	potential	to	limit	DNMT1	protein	expression,	and	therefore	methylation,	in	breast	cancer	cells	in	vitro.		 	
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